[
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Novartis to partner with AI-focused Relation on atopic diseases",
    "summary": "```json\n{\n  \"summary\": \"Novartis has entered into a partnership with UK-based biotech company Relation to discover and develop new drugs for certain immune diseases, specifically atopic diseases. This",
    "url": "https://endpoints.news/novartis-to-partner-with-relation-therapeutics-on-atopic-diseases/",
    "date": "2025-12-09",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "J&J-backed Cellular Origins raises $40M for cell therapy manufacturing",
    "summary": "```json\n{\n  \"summary\": \"UK-based cell therapy manufacturer Cellular Origins has raised $40 million in an over-subscribed Series A funding round led by Johnson & Johnson's venture capital arm. The comp",
    "url": "https://endpoints.news/jj-backed-cellular-origins-raises-40m-for-cell-therapy-manufacturing/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "China's SanegeneBio raises $110M in follow-up to metabolic deal with Lilly",
    "summary": "```json\n{\n  \"summary\": \"SanegeneBio, a Chinese biotech company, has raised $110 million in a Series B financing round. This funding comes one month after the company announced a partnership with Eli L",
    "url": "https://endpoints.news/chinas-sanegenebio-raises-110m-in-follow-up-to-metabolic-deal-with-lilly/",
    "date": "2025-12-09",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: Early in vivo CAR-T results like Kelonia's elicit excitement across the field",
    "summary": "```json\n{\n  \"summary\": \"Kelonia Therapeutics reported early clinical trial results at ASH25 showing that a single infusion of their ready-made CAR-T therapy achieved complete elimination of detectable",
    "url": "https://endpoints.news/ash25-early-in-vivo-car-t-results-like-kelonias-elicit-excitement-across-the-field/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "EpilepsyGTx gets $33M to test epilepsy gene therapy in Phase 1/2a",
    "summary": "```json\n{\n  \"summary\": \"EpilepsyGTx, a London-based biotech startup with two employees, has secured $33 million in Series A funding after more than two years of fundraising efforts. The funding will b",
    "url": "https://endpoints.news/epilepsygtx-gets-33m-to-test-epilepsy-gene-therapy-in-phase-1-2a/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Stealthy biotech Sidera Bio raises $109M; Assembly's data for oral herpes drugs",
    "summary": "```json\n{\n  \"summary\": \"Sidera Bio, a stealthy biotech company, has raised $109 million in Series funding from investors including Novo Holdings, Forbion, RA Capital Healthcare Fund, and Gilde Healthc",
    "url": "https://endpoints.news/stealthy-biotech-sidera-bio-raises-109m-assemblys-data-for-oral-herpes-drugs/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Seven biotechs eye $2.3B in public offerings after data readouts",
    "summary": "```json\n{\n  \"summary\": \"Seven biopharma companies announced plans to raise a combined total of $2.3 billion through public stock offerings. The announcements were made on Monday evening and Tuesday mo",
    "url": "https://endpoints.news/seven-biotechs-eye-2-3b-in-public-offerings-after-data-readouts/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Radial raises $50M to treat mental health in non-traditional ways",
    "summary": "```json\n{\n  \"summary\": \"Radial, a mental health startup, raised $50 million in combined Series A and seed funding. The company focuses on non-traditional mental health treatments using brain stimulati",
    "url": "https://endpoints.news/radial-raises-50m-to-treat-mental-health-in-non-traditional-ways/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancer",
    "summary": "```json\n{\n  \"summary\": \"BioNTech and Bristol Myers Squibb presented positive Phase 2 data at SABCS25 for their PD-L1xVEGF-A bispecific antibody in breast cancer. The companies suggest this bispecific ",
    "url": "https://endpoints.news/sabcs25-biontech-bms-unwrap-phase-2-data-for-pd-l1xvegf-bispecific-in-breast-cancer/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: Eli Lilly's Jaypirca makes first-line case, but ceiling may be capped",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly presented positive first-line data for Jaypirca at ASH25 in Orlando, following its recent approval for second-line leukemia patients. The company is seeking to expand",
    "url": "https://endpoints.news/ash25-eli-lillys-jaypirca-makes-first-line-case-but-ceiling-may-be-capped/",
    "date": "2025-12-09",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Eli Lilly will be 'aggressive' in spending GLP-1 money, top dealmaker Van Naarden says",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly's newly appointed chief dealmaker, Jacob Van Naarden, who was promoted to president of oncology, announced plans to aggressively deploy capital generated from the com",
    "url": "https://endpoints.news/eli-lilly-will-be-aggressive-in-spending-glp-1-money-says-top-dealmaker-van-naarden/",
    "date": "2025-12-09",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Cell and gene therapy benefits company Aradigm raises $20M",
    "summary": "```json\n{\n  \"summary\": \"Aradigm, a New York-based startup, has raised $20 million to help employers and health plans manage the costs of cell and gene therapies. The company aims to provide more predi",
    "url": "https://endpoints.news/cell-and-gene-therapy-benefits-company-aradigm-raises-20m/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Biosecure Act appears headed for final passage in defense bill",
    "summary": "```json\n{\n  \"summary\": \"A modified version of the Biosecure Act has advanced toward final passage as part of a defense bill in Congress. Despite being softened, the legislation could still significant",
    "url": "https://endpoints.news/biosecure-act-appears-headed-for-final-passage-in-defense-bill/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Notes from the 2025 SABEW med tech fellowship",
    "summary": "```json\n{\n  \"summary\": \"The text discusses observations from the 2025 SABEW med tech fellowship regarding increased attention to wearable devices. HHS Secretary Robert F. Kennedy Jr. is promoting wide",
    "url": "https://endpoints.news/notes-from-the-2025-sabew-med-tech-fellowship/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "FDA sets new, higher bar for CAR-T cancer treatments to prove superiority",
    "summary": "```json\n{\n  \"summary\": \"The FDA is raising approval standards for new CAR-T cancer therapies, requiring them to demonstrate superiority over existing treatments rather than just safety and efficacy. T",
    "url": "https://endpoints.news/fda-sets-new-higher-bar-for-car-t-cancer-treatments-to-prove-superiority/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "GSK walks away from remaining Ideaya programs",
    "summary": "```json\n{\n  \"summary\": \"GSK is terminating its five-year licensing agreement with Ideaya Biosciences, returning two clinical-stage programs to the California-based biotech company. The news was disclo",
    "url": "https://endpoints.news/gsk-walks-away-from-remaining-ideaya-programs/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "FDA misses PDUFA review deadline for Agios' thalassemia drug",
    "summary": "```json\n{\n  \"summary\": \"The FDA missed its PDUFA target action date for Agios Pharmaceuticals' thalassemia drug Pyrukynd, representing another regulatory delay for the company as it seeks to expand it",
    "url": "https://endpoints.news/fda-misses-pdufa-review-deadline-for-agios-thalassemia-drug/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: Novartis says its antibody ianalumab helps prolong control of rare blood disorder",
    "summary": "",
    "url": "https://endpoints.news/ash25-novartis-says-its-antibody-ianalumab-helps-prolong-control-of-rare-blood-disorder/",
    "date": "2025-12-09",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?",
    "summary": "```json\n{\n  \"summary\": \"Terns Pharmaceuticals announced in October that it is pivoting away from obesity to focus on cancer, specifically leukemia, where it will compete with Novartis. The announcemen",
    "url": "https://endpoints.news/ash25-will-a-biotechs-pivot-away-from-obesity-let-it-compete-with-novartis-in-leukemia/",
    "date": "2025-12-08",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Cogent’s mastocytosis drug continues momentum, helps treat sicker patients",
    "summary": "```json\n{\n  \"summary\": \"Cogent Biosciences reported positive data for its mastocytosis drug in patients with an advanced form of the blood disease. The results build on successful summer data and supp",
    "url": "https://endpoints.news/cogents-mastocytosis-drug-continues-momentum-helps-treat-sicker-patients/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiary",
    "summary": "```json\n{\n  \"summary\": \"Pfizer announced a $150 million upfront payment to acquire a small molecule GLP-1 program from a Fosun subsidiary. Pfizer CFO Dave Denton confirmed at the Jefferies Global Heal",
    "url": "https://endpoints.news/pfizer-to-pay-150m-upfront-for-small-molecule-glp-1-from-fosun-subsidiary/",
    "date": "2025-12-09",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "BioNTech, OncoC4’s antibody more than halves risk of death in Phase 3 lung cancer trial",
    "summary": "```json\n{\n  \"summary\": \"BioNTech and OncoC4 announced positive Phase 3 survival data for their antibody drug candidate gotistobart in lung cancer. The treatment reduced the risk of death by more than ",
    "url": "https://endpoints.news/biontech-oncoc4s-antibody-more-than-halves-risk-of-death-in-phase-3-lung-cancer-trial/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech Seeks an Experienced Quality Director",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech is recruiting for an experienced Quality Director position. This is a corporate hiring announcement with no specific details about drug development programs or partne",
    "url": "https://www.delsitech.com/delsitech-seeks-an-experienced-quality-director/",
    "date": "2025-12-09",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech announces a leadership change. Carl-Åke Carlsson, CEO of DelSiTech, leaves the company and the Board nominates Martti Hedman as Interim CEO.",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech has announced a leadership transition with CEO Carl-Åke Carlsson departing the company. The Board has appointed Martti Hedman to serve as Interim CEO following Carlss",
    "url": "https://www.delsitech.com/delsitech-announces-a-leadership-change-carl-ake-carlsson-ceo-of-delsitech-leaves-the-company-and-the-board-nominates-martti-hedman-as-interim-ceo/",
    "date": "2025-12-09",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approval",
    "summary": "",
    "url": "https://endpoints.news/dyne-says-duchenne-drug-succeeds-in-pivotal-study-heads-to-fda-for-approval/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech is Hiring a Process Engineer",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech is recruiting for a Process Engineer position. This is a corporate hiring announcement with no specific details about drug development, partnerships, or clinical prog",
    "url": "https://www.delsitech.com/delsitech-is-hiring-a-process-engineer/",
    "date": "2025-12-09",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Appointment of Outi Heikkilä as Chief Operations Officer",
    "summary": "```json\n{\n  \"summary\": \"Outi Heikkilä has been appointed as Chief Operations Officer. This is a corporate leadership announcement involving an executive appointment to a senior operational role.\",\n  \"",
    "url": "https://www.delsitech.com/appointment-of-outi-heikkila-as-chief-operations-officer/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC",
    "summary": "",
    "url": "https://endpoints.news/day-one-was-one-of-three-parties-interested-in-mersana-bihua-chen-and-cormorants-third-spac/",
    "date": "2025-12-08",
    "companies_detected": [
      "AbbVie"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "World Vaccine Congress Europe 2025 Amsterdam, October 13-16",
    "summary": "```json\n{\n  \"summary\": \"The World Vaccine Congress Europe 2025 is scheduled to take place in Amsterdam from October 13-16. This is a conference event focused on vaccine development and related topics ",
    "url": "https://www.delsitech.com/world-vaccine-congress-europe-2025-amsterdam-october-13-16/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28",
    "summary": "```json\n{\n  \"summary\": \"Partnership Opportunities in Drug Delivery 2025 is a conference taking place in Boston on October 27-28. The event focuses on drug delivery partnership opportunities in the pha",
    "url": "https://www.delsitech.com/partnership-opportunities-in-drug-delivery-2025-boston-october-27-28/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "CRS Annual Meeting & Exposition 2025 Philadelphia, July 14-18",
    "summary": "```json\n{\n  \"summary\": \"The Controlled Release Society (CRS) is hosting its Annual Meeting & Exposition in Philadelphia from July 14-18, 2025. This is a scientific conference focused on controlled rel",
    "url": "https://www.delsitech.com/crs-annual-meeting-exposition-2025-philadelphia-july-14-18/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "World Vaccine Congress 2025 Washington, April 21-24",
    "summary": "```json\n{\n  \"summary\": \"The World Vaccine Congress 2025 will be held in Washington from April 21-24. This is a conference event focused on vaccine development and related topics in the pharmaceutical ",
    "url": "https://www.delsitech.com/world-vaccine-congress-2025-washington-april-21-24/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)",
    "summary": "```json\n{\n  \"summary\": \"Medincell has published its consolidated half-year financial results for the period from April 1st, 2025 to September 30, 2025. This announcement provides stakeholders with an ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf",
    "date": "2025-12-09",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Drug Delivery and Formulation Summit 2025 Boston, September 15-16",
    "summary": "",
    "url": "https://www.delsitech.com/drug-delivery-and-formulation-summit-2025-boston-september-15-16/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults",
    "summary": "```json\n{\n  \"summary\": \"Teva Pharmaceuticals, in partnership with Medincell, has submitted a New Drug Application (NDA) to the U.S. FDA for TEV-'749/mdc-TJK, an olanzapine extended-release injectable ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf",
    "date": "2025-12-09",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [
      "olanzapine"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "BIO International Convention 2025 Boston, June 16-19",
    "summary": "```json\n{\n  \"summary\": \"The BIO International Convention 2025 will be held in Boston from June 16-19. This is a major industry conference bringing together biotech and pharma companies, investors, and",
    "url": "https://www.delsitech.com/bio-international-convention-2025-boston-june-16-19/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference",
    "summary": "```json\n{\n  \"summary\": \"Medincell's management will be presenting at two upcoming healthcare conferences: the 8th Annual Evercore Healthcare Conference and the Piper Sandler 37th Annual Healthcare Con",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Evercore-Piper_Sandler_EN_27112025.pdf",
    "date": "2025-12-09",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Awarded New Grant to Fight Malaria",
    "summary": "```json\n{\n  \"summary\": \"Medincell has been awarded a new grant to support its efforts in fighting malaria. The announcement indicates continued funding for the company's work in this therapeutic area,",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf",
    "date": "2025-12-09",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark",
    "summary": "```json\n{\n  \"summary\": \"Medincell has been selected to join the MSCI World Small Cap Index, which is a prominent global benchmark for small-cap stocks. This inclusion represents a significant corporat",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf",
    "date": "2025-12-09",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth",
    "summary": "```json\n{\n  \"summary\": \"Medincell has appointed Dr. Grace Kim as Chief Strategy Officer for U.S. Finance to support the company's next phase of capital growth in the United States. This corporate lead",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf",
    "date": "2025-12-09",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Videoconference and publication of half-year financial results, Tuesday, December 9, 2025",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_ConfHYR_01122025_EN.pdf",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)",
    "summary": "```json\n{\n  \"summary\": \"Medincell announced its participation in two upcoming healthcare investor conferences: the UBS Global Healthcare Conference in Palm Beach and the Stifel Healthcare Conference i",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_UBS-STIFEL_06112025_EN_vf.pdf",
    "date": "2025-12-09",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "[Replay] Jefferies Global Healthcare Conference 2025",
    "summary": "",
    "url": "https://wsw.com/webcast/jeff332/medcl/1970687",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025",
    "summary": "```json\n{\n  \"summary\": \"Teva's UZEDY® (risperidone extended-release injectable suspension) continues to demonstrate strong commercial growth. The company is preparing to submit a New Drug Application ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [
      "olanzapine"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the January-September 2025 period. This is a routine corporate disclosure providing updates on the company's financia",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has been named as a finalist in the Fierce Innovation Awards Life Sciences Edition 2025. This recognition highlights the company's innovative contributions to the life s",
    "url": "https://nanexa.com/mfn_news/nanexa-named-as-finalist-in-fierce-innovation-awards-life-sciences-edition-2025/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)",
    "summary": "```json\n{\n  \"summary\": \"Medincell announced its participation in the 2025 Truist Securities Biopharma Symposium taking place in New York. This is a corporate event where the company will likely presen",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_Truist_22102025_EN_vf.pdf",
    "date": "2025-12-09",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved an expanded indication for UZEDY (risperidone) extended-release injectable suspension for the treatment of adults with Bipolar I Disorder. This represents ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_UZEDY-BDI_EN_10102025_vf.pdf",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [
      "risperidone"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-June 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the period from January to June 2025. This is a routine corporate disclosure providing updates on the company's finan",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-june-2025/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "summary": "```json\n{\n  \"summary\": \"Unable to analyze the content as the provided text only contains 'Download attachment' without any actual biotech/pharma news content. No companies, molecules, technologies, or",
    "url": "https://storage.mfn.se/5d2c8421-0163-4592-8c9e-43752659a104/nanexa-interim-report-january-june-2025.pdf",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "summary": "```json\n{\n  \"summary\": \"Unable to analyze the content as the provided text only contains 'Download attachment' without any actual biotech/pharma news content. No companies, molecules, technologies, or",
    "url": "https://storage.mfn.se/ab91ff14-4c8b-4c40-85a9-996052a19950/nanexa-interim-report-january-september-2025.pdf",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/teleflex-inks-2b-divestment-deals-oem-urology-and-acute-care-units\" hreflang=\"en\">Teleflex inks $2B in divestment deals for OEM, urology and acute care units</a>",
    "summary": "```json\n{\n  \"summary\": \"Teleflex is divesting three business units in deals totaling approximately $2 billion. Private equity firms Montagu and Kohlberg are acquiring the OEM division for $1.5 billion",
    "url": "https://www.fiercebiotech.com/medtech/teleflex-inks-2b-divestment-deals-oem-urology-and-acute-care-units",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/medline-sets-terms-massive-537b-nasdaq-ipo\" hreflang=\"en\">Medline sets terms for massive $5.37B Nasdaq IPO</a>",
    "summary": "```json\n{\n  \"summary\": \"Medline, a medical device manufacturing and distribution company, has set terms for a massive $5.37 billion IPO on Nasdaq. The company could achieve a valuation of approximatel",
    "url": "https://www.fiercebiotech.com/medtech/medline-sets-terms-massive-537b-nasdaq-ipo",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/cro/fda-clears-1st-ai-drug-development-tool-reading-mash-images\" hreflang=\"en\">FDA qualifies 1st AI drug development tool for reading MASH images</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has qualified its first artificial intelligence tool designed to assist drug developers in evaluating metabolic dysfunction-associated steatohepatitis (MASH), formerly ",
    "url": "https://www.fiercebiotech.com/cro/fda-clears-1st-ai-drug-development-tool-reading-mash-images",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-exicure-rebounds-phase-2-win-90-blood-cell-mobilization-myeloma\" hreflang=\"en\">ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma</a>",
    "summary": "```json\n{\n  \"summary\": \"Exicure reported positive phase 2 results for its investigational small molecule in multiple myeloma, achieving approximately 90% mobilization of blood-forming cells. This succ",
    "url": "https://www.fiercebiotech.com/biotech/ash-exicure-rebounds-phase-2-win-90-blood-cell-mobilization-myeloma",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-novartis-details-ianalumabs-phase-3-win-rare-blood-disease\" hreflang=\"en\">ASH: Novartis details ianalumab's phase 3 win in rare blood disease</a>",
    "summary": "```json\n{\n  \"summary\": \"Novartis presented detailed phase 3 results for ianalumab in treating a rare autoimmune blood disorder at ASH (American Society of Hematology). The data indicate that ianalumab",
    "url": "https://www.fiercebiotech.com/biotech/ash-novartis-details-ianalumabs-phase-3-win-rare-blood-disease",
    "date": "2025-12-09",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Read the presentation",
    "summary": "```json\n{\n  \"summary\": \"The text provided contains only the phrase 'Read the presentation' without any substantive biotech/pharma news content. No specific companies, molecules, technologies, or thera",
    "url": "https://nanexa.com/wp-content/uploads/2025/11/PODD-Oct-2025.pdf",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug\" hreflang=\"en\">Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer has entered into a $1.9 billion biobucks deal with a Fosun unit, including $150 million upfront, to acquire a GLP-1 drug for obesity treatment. This partnership continue",
    "url": "https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug",
    "date": "2025-12-09",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma\" hreflang=\"en\">ASH: J&amp;J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma</a>",
    "summary": "```json\n{\n  \"summary\": \"Johnson & Johnson presented positive trial data at ASH for a combination therapy involving Tecvayli, a bispecific antibody for multiple myeloma. The data suggests this combinat",
    "url": "https://www.fiercebiotech.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ose-narrows-focus-conserve-cash-expense-wider-pipeline\" hreflang=\"en\">Ose narrows focus to conserve cash at expense of wider pipeline</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/ose-narrows-focus-conserve-cash-expense-wider-pipeline",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech\" hreflang=\"en\">Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech</a>",
    "summary": "```json\n{\n  \"summary\": \"Novartis has entered into a $1.7 billion biobucks partnership with a British AI-enabled biotech company. The collaboration focuses on discovering new targets for immuno-dermato",
    "url": "https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech",
    "date": "2025-12-09",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/weight-loss-windfall-lilly-looks-become-backbone-global-innovation\" hreflang=\"en\">With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec</a>",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly, riding high on the success of its best-selling medication tirzepatide and achieving a record $1 trillion valuation, plans to leverage its substantial financial windf",
    "url": "https://www.fiercebiotech.com/biotech/weight-loss-windfall-lilly-looks-become-backbone-global-innovation",
    "date": "2025-12-09",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fda-steers-cancer-car-t-developers-toward-randomized-superiority-trials-policy-shift\" hreflang=\"en\">FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA is implementing a policy shift requiring CAR T-cell therapy developers in oncology to demonstrate superiority over existing treatments through randomized trials. This r",
    "url": "https://www.fiercebiotech.com/biotech/fda-steers-cancer-car-t-developers-toward-randomized-superiority-trials-policy-shift",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/gsk-cuts-cord-longtime-ideaya-collaboration-letting-go-2-programs\" hreflang=\"en\">GSK cuts the cord on Ideaya collaboration, letting go of 2 programs</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/gsk-cuts-cord-longtime-ideaya-collaboration-letting-go-2-programs",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/dyne-readies-fda-push-after-dmd-exon-51-med-excels-trial\" hreflang=\"en\">Dyne readies FDA push after DMD exon 51 med excels in trial</a>",
    "summary": "```json\n{\n  \"summary\": \"Dyne Therapeutics announced positive trial results for its DMD (Duchenne muscular dystrophy) exon 51 skipping therapy and is preparing to submit to the FDA. CEO John Cox stated",
    "url": "https://www.fiercebiotech.com/biotech/dyne-readies-fda-push-after-dmd-exon-51-med-excels-trial",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/dr-reddys-pens-370m-pact-rights-immuteps-phase-3-stage-immunotherapy-certain-markets\" hreflang=\"en\">Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets </a>",
    "summary": "```json\n{\n  \"summary\": \"Dr. Reddy's Laboratories has entered into a $370 million deal with Immutep for rights to the Australian biotech's phase 3-stage LAG-3 immunotherapy candidate in certain territo",
    "url": "https://www.fiercebiotech.com/biotech/dr-reddys-pens-370m-pact-rights-immuteps-phase-3-stage-immunotherapy-certain-markets",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-merck-mulls-future-polycythemia-program-while-takeda-takes-ph-3-victory-lap\" hreflang=\"en\">ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/ash-merck-mulls-future-polycythemia-program-while-takeda-takes-ph-3-victory-lap",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/fda-clears-resmed-ai-personalizing-cpap-settings\" hreflang=\"en\">FDA clears Resmed AI for personalizing CPAP settings</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has cleared ResMed's artificial intelligence-powered system for personalizing CPAP machine settings. The AI-enabled approach is designed to optimize therapy for patient",
    "url": "https://www.fiercebiotech.com/medtech/fda-clears-resmed-ai-personalizing-cpap-settings",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/stryker-promotes-stiles-president-coo-lead-its-ma-growth-strategy\" hreflang=\"en\">Stryker promotes new president, COO to help lead its M&amp;A strategy</a>",
    "summary": "```json\n{\n  \"summary\": \"Stryker, a medical technology company, has promoted Spencer Stiles, a 27-year veteran of the company, to the positions of president and chief operating officer. This leadership",
    "url": "https://www.fiercebiotech.com/medtech/stryker-promotes-stiles-president-coo-lead-its-ma-growth-strategy",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/sponsored/agc-biologics-leader-warns-looming-microbial-manufacturing-crunch\" hreflang=\"en\">Is biopharma facing a microbial manufacturing crunch?</a>",
    "summary": "```json\n{\n  \"summary\": \"AGC Biologics' Dieter Kramer discusses the growing demand for late-phase microbial manufacturing capacity in the biopharma industry, warning of a potential capacity crunch. The",
    "url": "https://www.fiercebiotech.com/sponsored/agc-biologics-leader-warns-looming-microbial-manufacturing-crunch",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/mirum-nets-bluejay-and-its-phase-3-stage-hepatitis-drug-620m\" hreflang=\"en\">Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M</a>",
    "summary": "```json\n{\n  \"summary\": \"Mirum Pharmaceuticals is acquiring Bluejay Therapeutics for $620 million in cash and stock. The acquisition centers on Bluejay's phase 3-stage hepatitis drug candidate.\",\n  \"ev",
    "url": "https://www.fiercebiotech.com/biotech/mirum-nets-bluejay-and-its-phase-3-stage-hepatitis-drug-620m",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/sponsored/how-ai-and-real-world-evidence-are-powering-smarter-decisions-across-drug-and-device\" hreflang=\"en\">How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle</a>",
    "summary": "```json\n{\n  \"summary\": \"The article discusses how pharmaceutical and biotech companies are leveraging artificial intelligence and real-world evidence to make more informed decisions throughout the dru",
    "url": "https://www.fiercebiotech.com/sponsored/how-ai-and-real-world-evidence-are-powering-smarter-decisions-across-drug-and-device",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/wave-structure-move-assets-clinical-ladder-biotechs-obesity-development-blitz-rolls\" hreflang=\"en\">Wave, Structure stocks double on obesity data readouts</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/wave-structure-move-assets-clinical-ladder-biotechs-obesity-development-blitz-rolls",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/chinas-ascletis-reports-77-weight-loss-oral-glp-1-contender-us-phase-2-study\" hreflang=\"en\">China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study</a>",
    "summary": "```json\n{\n  \"summary\": \"Ascletis Pharma reported 7.7% weight loss results for the highest dose of its oral GLP-1 candidate in a US Phase 2 clinical study. The company is competing in the highly contes",
    "url": "https://www.fiercebiotech.com/biotech/chinas-ascletis-reports-77-weight-loss-oral-glp-1-contender-us-phase-2-study",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/sponsored/new-era-parkinsons-solengepras-leads-shift-beyond-dopamine\" hreflang=\"en\">A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine</a>",
    "summary": "```json\n{\n  \"summary\": \"Cerevance is developing Solengepras, a novel non-dopaminergic treatment for Parkinson's disease that represents a shift away from traditional dopamine-based therapies. This inn",
    "url": "https://www.fiercebiotech.com/sponsored/new-era-parkinsons-solengepras-leads-shift-beyond-dopamine",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/research/amphistas-targeted-glue-sticks-landing-aml-test-supporting-push-clinic\" hreflang=\"en\">Amphista's targeted glue sticks the landing in AML test, supporting push into the clinic</a>",
    "summary": "```json\n{\n  \"summary\": \"Amphista Therapeutics has reported positive preclinical data for its protein degrader in acute myeloid leukemia (AML). The company, which has Big Pharma partnerships, is target",
    "url": "https://www.fiercebiotech.com/research/amphistas-targeted-glue-sticks-landing-aml-test-supporting-push-clinic",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-now-has-merck-az-and-sanofi-rsv-shots-infants-its-crosshairs-reuters\" hreflang=\"en\">FDA now has Merck, AZ and Sanofi RSV shots for infants in its crosshairs: Reuters</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA is investigating the safety of RSV shots for infants manufactured by Merck, AstraZeneca, and Sanofi, according to Reuters. This examination comes as an FDA official sta",
    "url": "https://www.fiercepharma.com/pharma/fda-now-has-merck-az-and-sanofi-rsv-shots-infants-its-crosshairs-reuters",
    "date": "2025-12-09",
    "companies_detected": [
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/eye-ai-imre-hires-nadine-lafond-ogilvy-fill-ceo-vacancy\" hreflang=\"en\">With eye on AI, Imre hires Nadine Lafond from Ogilvy Health to fill CEO vacancy</a>",
    "summary": "```json\n{\n  \"summary\": \"Ad agency Imre has appointed Nadine Lafond as its new CEO, recruiting her from Ogilvy Health. The hire comes as Imre focuses on artificial intelligence capabilities.\",\n  \"event",
    "url": "https://www.fiercepharma.com/marketing/eye-ai-imre-hires-nadine-lafond-ogilvy-fill-ceo-vacancy",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/its-future-still-limbo-csl-seqirus-debuts-1b-flu-shot-antivenom-plant-australia\" hreflang=\"en\">Its future still in limbo, CSL Seqirus debuts $1B flu shot, antivenom plant in Australia</a>",
    "summary": "```json\n{\n  \"summary\": \"CSL has opened a new $1 billion manufacturing facility in Melbourne, Australia for its Seqirus vaccine division, which will produce cell-based flu shots and antivenom products.",
    "url": "https://www.fiercepharma.com/manufacturing/its-future-still-limbo-csl-seqirus-debuts-1b-flu-shot-antivenom-plant-australia",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/viatris-returns-stake-biocon-biologics-815m-setting-biosimilar-market-re-entry-biocon\" hreflang=\"en\">Biocon buys out Viatris and others from biosimilar subsidiary</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/viatris-returns-stake-biocon-biologics-815m-setting-biosimilar-market-re-entry-biocon",
    "date": "2025-12-09",
    "companies_detected": [
      "Biocon"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/once-public-now-private-gamida-cell-scores-2nd-fda-nod-stem-cell-therapy-omisirge\" hreflang=\"en\">Once public, now private, Gamida Cell scores 2nd FDA nod for stem cell therapy Omisirge</a>",
    "summary": "```json\n{\n  \"summary\": \"Gamida Cell, now a private company after previously being public, has received FDA approval to expand the use of its cell therapy Omisirge for treating severe aplastic anemia. ",
    "url": "https://www.fiercepharma.com/pharma/once-public-now-private-gamida-cell-scores-2nd-fda-nod-stem-cell-therapy-omisirge",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/biontechs-ctla-4-drug-improves-survival-phase-3-cancer-trial-poses-tolerability-challenge\" hreflang=\"en\">BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/biontechs-ctla-4-drug-improves-survival-phase-3-cancer-trial-poses-tolerability-challenge",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/biosecure-legislation-makes-way-key-us-defense-bill-teeing-potential-china-biopharma\" hreflang=\"en\">Biosecure Act slips into key US defense bill, teeing up potential China biopharma constraints in '26</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/biosecure-legislation-makes-way-key-us-defense-bill-teeing-potential-china-biopharma",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma\" hreflang=\"en\">ASH: J&amp;J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma</a>",
    "summary": "```json\n{\n  \"summary\": \"Johnson & Johnson presented positive trial data at ASH for a combination therapy involving its multiple myeloma bispecific antibody Tecvayli as a second-line treatment option. ",
    "url": "https://www.fiercepharma.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/lilly-oncology-chief-sees-jaypirca-sweet-spot-second-line-cll-despite-first-line-btk-trial\" hreflang=\"en\">ASH: Lilly oncology chief sees sweet spot for Jaypirca in 2nd-line CLL despite 1st-line trial wins</a>",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly's oncology president Jacob Van Naarden stated that despite positive phase 3 data supporting first-line approval of BTK inhibitor Jaypirca in chronic lymphocytic leuke",
    "url": "https://www.fiercepharma.com/pharma/lilly-oncology-chief-sees-jaypirca-sweet-spot-second-line-cll-despite-first-line-btk-trial",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fast-rising-ucb-set-file-approval-fintepla-3rd-epileptic-disorder\" hreflang=\"en\">Fast-rising UCB set to file for Fintepla approval in 3rd epileptic disorder after trial win</a>",
    "summary": "```json\n{\n  \"summary\": \"UCB announced plans to file for regulatory approval of Fintepla for treatment of cyclin-dependent kinase-like-5 (CDKL5) deficiency disorder, marking the third epileptic conditi",
    "url": "https://www.fiercepharma.com/pharma/fast-rising-ucb-set-file-approval-fintepla-3rd-epileptic-disorder",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/amgen-inks-la-sports-entertainment-partnership-setting-2026-world-cup-presence\" hreflang=\"en\">Amgen inks LA sports, entertainment partnership, setting up 2026 World Cup presence</a>",
    "summary": "```json\n{\n  \"summary\": \"Amgen has announced a new sports and entertainment partnership in Greater Los Angeles, its hometown area. The partnership is designed to increase the company's visibility and i",
    "url": "https://www.fiercepharma.com/marketing/amgen-inks-la-sports-entertainment-partnership-setting-2026-world-cup-presence",
    "date": "2025-12-09",
    "companies_detected": [
      "Amgen"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025\" hreflang=\"en\">Regulatory tracker: Agios awaits FDA decision as target date passes</a>",
    "summary": "```json\n{\n  \"summary\": \"Fierce Pharma is maintaining a regulatory tracker for in-market pharmaceutical products, monitoring their regulatory progress including geographic expansions and new indication",
    "url": "https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/how-one-companys-focus-patient-journey-fuels-innovation-across-spectrum-medicine\" hreflang=\"en\">Beyond the treatment: Innovation on the human side of medicine</a>",
    "summary": "```json\n{\n  \"summary\": \"This is a sponsored content piece highlighting how a pharmaceutical company's focus on understanding the patient journey is driving innovation to make healthcare more intuitive",
    "url": "https://www.fiercepharma.com/sponsored/how-one-companys-focus-patient-journey-fuels-innovation-across-spectrum-medicine",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/pfizer-lilly-jj-and-more-see-inclusions-chinas-first-batch-picks-new-private-insurance\" hreflang=\"en\">Meds from Pfizer, Lilly, J&amp;J and more secure spots in China's 1st private insurance formulary</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/pfizer-lilly-jj-and-more-see-inclusions-chinas-first-batch-picks-new-private-insurance",
    "date": "2025-12-09",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/data-decisions-how-walgreens-powering-smarter-pharma-strategies\" hreflang=\"en\">From data to decisions: how Walgreens is powering smarter pharma strategies</a>",
    "summary": "```json\n{\n  \"summary\": \"Walgreens is leveraging retail pharmacy data insights to help pharmaceutical companies identify patient barriers and improve medication access and adherence. The data-driven ap",
    "url": "https://www.fiercepharma.com/sponsored/data-decisions-how-walgreens-powering-smarter-pharma-strategies",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/agentic-ai-can-fix-healthcares-communications-crisis-heres-how\" hreflang=\"en\">Agentic AI can fix healthcare’s communications crisis – here’s how</a>",
    "summary": "```json\n{\n  \"summary\": \"This article discusses how Agentic AI technology can address communication breakdowns in healthcare settings. The piece argues that when healthcare communication fails, patient",
    "url": "https://www.fiercepharma.com/sponsored/agentic-ai-can-fix-healthcares-communications-crisis-heres-how",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-csl-proves-hemophilia-b-gene-therapy-hemgenix-holds-after-5-years-post-dosing\" hreflang=\"en\">ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years</a>",
    "summary": "```json\n{\n  \"summary\": \"CSL reported 5-year follow-up data from its Hope-B study showing that Hemgenix, a one-time gene therapy for hemophilia B, reduced annualized bleeding rates by 90% by the fifth ",
    "url": "https://www.fiercepharma.com/pharma/ash-csl-proves-hemophilia-b-gene-therapy-hemgenix-holds-after-5-years-post-dosing",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/cdcs-acip-votes-tweak-long-standing-hepatitis-b-vaccine-guidance-infants-prompting-backlash\" hreflang=\"en\">CDC's ACIP votes to change longstanding hepatitis B vaccine guidance for newborns, prompting backlash </a>",
    "summary": "```json\n{\n  \"summary\": \"The CDC's Advisory Committee on Immunization Practices (ACIP) voted 8-2 to change the longstanding guidance for hepatitis B vaccination in newborns, moving to an individual-bas",
    "url": "https://www.fiercepharma.com/pharma/cdcs-acip-votes-tweak-long-standing-hepatitis-b-vaccine-guidance-infants-prompting-backlash",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-pfizer-aiming-level-hemophilia-playing-field-trots-out-hympavzi-inhibitors-data\" hreflang=\"en\">ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer has released phase 3 clinical trial results for its hemophilia drug Hympavzi, positioning it to compete with rival therapies from Sanofi (Qfitlia) and Novo Nordisk (Alhe",
    "url": "https://www.fiercepharma.com/pharma/ash-pfizer-aiming-level-hemophilia-playing-field-trots-out-hympavzi-inhibitors-data",
    "date": "2025-12-09",
    "companies_detected": [
      "Novo Nordisk",
      "Pfizer",
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-regeneron-does-subtraction-bids-move-bispecifics-earlier-treatment-blood-cancers\" hreflang=\"en\">ASH: Regeneron eyes simpler regimens in bid to move bispecifics into earlier blood cancer treatment</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/ash-regeneron-does-subtraction-bids-move-bispecifics-earlier-treatment-blood-cancers",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/abbvie-revs-skyrizi-spending-top-tv-ad-totals-november-edging-out-jjs-tremfya\" hreflang=\"en\">AbbVie revs up Skyrizi spending to top TV ad totals in November, edging out J&amp;J's Tremfya</a>",
    "summary": "```json\n{\n  \"summary\": \"AbbVie's Skyrizi topped TV advertising spending in November, surpassing Johnson & Johnson's Tremfya. This followed a record-setting October for pharmaceutical TV ad spending, w",
    "url": "https://www.fiercepharma.com/marketing/abbvie-revs-skyrizi-spending-top-tv-ad-totals-november-edging-out-jjs-tremfya",
    "date": "2025-12-09",
    "companies_detected": [
      "AbbVie"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/biopharma-dealmaking-landscape-and-what-expect-2026\" hreflang=\"en\">The biopharma dealmaking landscape and what to expect in 2026</a>",
    "summary": "```json\n{\n  \"summary\": \"EY's Arda Ural discusses biopharma dealmaking trends and valuation shifts on Fierce Pharma's 'The Top Line' podcast. The conversation covers the current dealmaking landscape an",
    "url": "https://www.fiercepharma.com/pharma/biopharma-dealmaking-landscape-and-what-expect-2026",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/bms-scores-5th-indication-breyanzi-fda-marginal-zone-lymphoma-nod\" hreflang=\"en\">BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod</a>",
    "summary": "```json\n{\n  \"summary\": \"Bristol Myers Squibb's Breyanzi has received FDA approval for marginal zone lymphoma, marking its fifth indication. This makes Breyanzi the first CAR-T therapy approved for mar",
    "url": "https://www.fiercepharma.com/pharma/bms-scores-5th-indication-breyanzi-fda-marginal-zone-lymphoma-nod",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/cuban-tells-trump-waiving-fda-approval-fees-would-spur-generics-manufacturing-us\" hreflang=\"en\">Lowering FDA fees would spur generics manufacturing in US, Mark Cuban says</a>",
    "summary": "```json\n{\n  \"summary\": \"Mark Cuban, co-founder of Cost Plus Drugs, stated that his online pharmacy company would manufacture generic drugs in the United States if the FDA eliminated approval fees. Cub",
    "url": "https://www.fiercepharma.com/manufacturing/cuban-tells-trump-waiving-fda-approval-fees-would-spur-generics-manufacturing-us",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out\" hreflang=\"en\">'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out</a>",
    "summary": "```json\n{\n  \"summary\": \"The mRNA industry coalition has issued a statement expressing concern about the current instability at the FDA, characterizing it as 'unprecedented turmoil.' The group warns th",
    "url": "https://www.fiercepharma.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/avalere-health-hires-sarah-hall-lead-us-marketing-team-through-politically-dynamic-period\" hreflang=\"en\">Avalere Health hires Sarah Hall to lead US marketing team through 'politically dynamic' period</a>",
    "summary": "```json\n{\n  \"summary\": \"Avalere Health has appointed Sarah Hall as president of U.S. marketing to lead the company's marketing team. Hall is a direct-to-consumer expert who will guide the team through",
    "url": "https://www.fiercepharma.com/marketing/avalere-health-hires-sarah-hall-lead-us-marketing-team-through-politically-dynamic-period",
    "date": "2025-12-09",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  }
]